Morphic Announces Corporate Highlights and Financial Results for the Full Year 2019
February 27, 2020 16:05 ET
|
Morphic Therapeutic
WALTHAM, Mass., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (NASDAQ: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Presents Positive Preclinical Data Supporting MORF-057 as an Oral Inhibitor of the α4β7 Integrin and Potential Treatment for Inflammatory Bowel Disease
February 14, 2020 11:29 ET
|
Morphic Therapeutic
Oral presentation at ECCO highlights MORF-057 as a potent, selective and orally available small molecule development candidate Mechanism of action demonstrated in in vitro and in vivo models ...
Morphic to Present at the 38th Annual J.P. Morgan Healthcare Conference
January 08, 2020 12:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., Jan. 08, 2020 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic to Present at the Jefferies 2019 London Healthcare Conference
November 18, 2019 16:15 ET
|
Morphic Therapeutic
WALTHAM, Mass., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Announces Corporate Highlights and Third Quarter 2019 Financial Results
November 12, 2019 16:24 ET
|
Morphic Therapeutic
MORF-720, αvβ6-targeted oral integrin inhibitor IND now anticipated in the second half of 2020α4β7-targeted oral integrin inhibitor candidate for IBD on track for IND by mid-2020Morphic ends third...
Morphic to Present at the Wells Fargo Securities 2019 Healthcare Conference
August 30, 2019 13:00 ET
|
Morphic Therapeutic
WALTHAM, Mass., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious...
Morphic Announces Corporate Highlights and Second Quarter 2019 Financial Results
August 12, 2019 06:30 ET
|
Morphic Therapeutic
- Successful IPO provides more than $100 million in gross proceeds to advance leading oral integrin development pipeline and MInT discovery platform - Company remains on track to file INDs for its...